What is it?
Joint findings are modest and population-specific
8A 2023 trial randomized 88 adults with mild knee pain to MSM or placebo. Some knee questionnaire scores improved after 12 weeks, with 80 participants included in the efficacy analysis. This does not establish a benefit for everyone, prevention of joint injury or cognitive performance.
Exercise recovery remains uncertain
6In 22 half-marathon participants, overall pain comparisons and measured oxidative-stress and muscle-damage outcomes were not significant. An exploratory pain trend is a reason for further study, rather than a reliable recovery promise.
Names, aliases and forms
Mechanisms of action
Mechanisms are not outcome evidence
11Laboratory and animal studies explore oxidative-stress and inflammation pathways. Human exposure to MSM is established, but pathway findings do not prove improved cognition, cartilage repair or a general detox effect.
Potential effects and evidence map
Grade E for cognitive use: no convincing focus or memory benefit is established. Joint comfort has limited human evidence, and exercise recovery findings are mixed. A larger military-trainee trial found no significant mood or knee-symptom benefit.
Exercise recovery evidence is mixed; a small half-marathon trial did not establish a significant benefit.
Typical dosages and timing
This compact range describes commonly studied supplemental intake, not a recommended dose. Trials differ in population, amount and outcome; some older joint studies used larger amounts. A universal effective dose or dose-response advantage has not been established.
Timing & effect horizon
The featured study window is the assessment period of an adult knee trial. It is not a single-dose effect duration or a recommended cycle. Reliable cognitive onset, clinical The time for blood levels to fall by half during the final elimination phase.Source and cycling protocols remain unestablished. Meal timing has not been shown to improve MSM efficacy.
Safety, side effects and risk profile
Mild digestive discomfort can occur; short-term studies generally describe good tolerability.
Headache has been reported as a mild possible adverse effect; its frequency is uncertain.
MSM-only drug-interaction evidence is sparse. Combination products require assessment of every ingredient.
Adequate supplemental-use safety evidence for pregnancy, breastfeeding or children is lacking.
Short studies cannot establish long-term or rare-event safety. Joint findings do not establish cognitive benefits.
United States, as of 14 October 2026: GRN 229 concerns specified food uses; it is not approval of MSM as a medicine.
The base rating covers typical oral intake by generally healthy adults over the short periods represented in trials. No common clinically meaningful harm signal justifies a higher label; mild digestive upset or headache remain possible. This rating does not establish indefinite use or safety at any dose.
Interactions and cautions
Human MSM-only interaction studies are sparse. MSM blends may add glucosamine or chondroitin, whose warfarin-related interaction reports cannot be attributed to MSM itself. An ingredient-by-ingredient interaction check matters for medication users.
Legal and regulatory status
The U.S. FDA inventory records a no-questions response for Bergstrom Nutrition's GRAS Notice 229, covering specified MSM food uses and levels. This is not FDA approval of MSM as a medicine or confirmation of supplement efficacy. Other markets and import requirements need their own assessment.
Practical buying and quality notes
- For a single-ingredient product labeled 750 mg per capsule, four capsules supply 3 g of MSM. Compare powders by price per gram and capsules by labeled MSM mass, rather than comparing a per-capsule price with a per-gram price. In a blend, use the declared MSM amount rather than the total formula weight. This is serving math, not a dosing recommendation.
- Look for batch-specific identity and purity testing, a dated certificate of analysis, contaminant results and a clear serving amount. A scoop volume is not proof of mass accuracy. Some indexed offers have old crawl dates: confirm current price, stock, package size and shipping on the merchant page before comparing total cost.
FAQ
Is there an effective MSM dose for focus?
11No validated dose for focus or memory is established. Joint-study dosing cannot answer that question, and increasing the amount has not been shown to create a cognitive benefit.
How long was MSM studied, and is a cycle established?
8The featured knee study assessed daily use over 12 weeks. That observation window does not define when benefits start, how long they last after stopping or an effective cycling schedule.
What did the military-trainee trial find?
9A trial in 180 military trainees found no significant improvement in knee or mood questionnaire scores versus placebo. That negative finding limits preventive and mood claims; it does not settle every joint-comfort use case.
References
- PubChem Compound Summary for CID 6213, Methylsulfonylmethane.
- Butawan M, Benjamin RL, Bloomer RJ. Methylsulfonylmethane: applications and safety of a dietary supplement. Nutrients. 2017.
- Kim LS, Axelrod LJ, Howard P, et al. MSM knee osteoarthritis pilot trial. Osteoarthritis Cartilage. 2006.
- Debbi EM, Agar G, Fichman G, et al. MSM randomized controlled knee osteoarthritis study. BMC Complement Altern Med. 2011.
- Brien S, Prescott P, Lewith G. DMSO/MSM knee osteoarthritis meta-analysis. Evid Based Complement Alternat Med. 2011.
- Withee ED, Tippens KM, Dehen R, et al. MSM after half-marathon exertion: randomized placebo-controlled trial. J Int Soc Sports Nutr. 2017.
- Nakhostin-Roohi B, Barmaki S, Khoshkhahesh F, Bohlooli S. MSM and oxidative stress after acute exercise. J Pharm Pharmacol. 2011.
- Toguchi A, Noguchi N, Kanno T, et al. MSM and mild knee pain quality-of-life trial. Nutrients. 2023.
- Tennent DJ, Hylden CM, Kocher BK, et al. A randomized controlled trial evaluating methylsulfonylmethane versus placebo to prevent knee pain in military initial entry trainees. US Army Med Dep J. 2017; (3-17):21-25.
- Crawford P, Crawford A, Nielson F, Lystrup R. Methylsulfonylmethane for treatment of low back pain: A safety analysis of a randomized, controlled trial. Complement Ther Med. 2019;45:85-88.
- Yoon Y, Hwang J, Kim J, et al. Methylsulfonylmethane as a Bioactive Nutraceutical: Molecular Mechanisms, Clinical Evidence, Combination Therapy, Dosing, and Safety. Int J Mol Sci. 2026;27(20):8967.
- U.S. Food and Drug Administration. GRAS Notice GRN 229: Methylsulfonylmethane. Inventory entry and additional correspondence.